Cytomos

Cytomos is pioneering a novel Process Analytical Technology (PAT) for the biopharma industry with its AuraCyt® platform, commercialized as the Celledonia® system. This technology measures intrinsic cell properties without labels or complex assays, aiming to deliver rapid, predictive insights to accelerate bioprocess optimization and cell therapy manufacturing. The company is investor-backed, collaborates with large biotechs and pharma on proof-of-concept studies, and targets becoming the leading partner for real-time, single-cell analytics in bioprocessing. Its mission is to streamline drug discovery, development, and manufacturing through real-time monitoring and automation-enabling data.

AuraCyt® / Celledonia®: A label-free, real-time single-cell analysis platform that measures intrinsic biophysical/biochemical properties to predict cell performance in bioprocessing. It uses microfluidics and proprietary signal processing for rapid, assay-free insights.

Cytomos competes with established life science tools companies offering flow cytometers and analyzers (e.g., Beckman Coulter, Sartorius) and newer startups in label-free cell analysis (e.g., using impedance, imaging). Its differentiation lies in the combination of label-free operation, real-time predictive output, and specific application focus on bioprocessing decision-making.